Nektar Therapeutics (NKTR)

Jul 23, 2025

Nektar Therapeutics's Options: A Look at What the Big Money is Thinking - Nasdaq

Jul 23, 2025

Jul 23, 2025

Nektar Therapeutics Stock Analysis and ForecastStrong return on investment - jammulinksnews.com

Jul 23, 2025

Jul 23, 2025

What drives Nektar Therapeutics stock priceTriple-digit returns - Autocar Professional

Jul 23, 2025

Jul 22, 2025

Is Nektar Therapeutics a good long term investmentBreakneck growth rates - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

What analysts say about Nektar Therapeutics stockExceptional profit velocity - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

Nektar Therapeutics Launches By Triple Digits On Eczema Grand Slam - MSN

Jul 21, 2025

Jul 17, 2025

Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin - MSN

Jul 17, 2025

Jul 14, 2025

Why Nektar Therapeutics Stock Dived by 3% Today - AOL.com

Jul 14, 2025

Jul 13, 2025

Nektar Therapeutics Announces Pricing of $100 Million Public Offering - 富途牛牛

Jul 13, 2025

Jul 10, 2025

B-Cell Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi - Barchart.com

Jul 10, 2025

Jul 10, 2025

Interleukin-2 Inhibitors Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Yahoo Finance

Jul 10, 2025

Jul 08, 2025

Rezpegaldesleukin Potentially Promising for Atopic Dermatitis - AJMC

Jul 08, 2025

Jul 07, 2025

5 Second-Half Biopharma Milestones To Watch - BioSpace

Jul 07, 2025

Jul 04, 2025

Nektar Therapeutics' experimental eczema drug meets main goal of mid-stage trial - MSN

Jul 04, 2025

Jul 02, 2025

Nektar Therapeutics Announces Closing of $115 Million Public Off - GuruFocus

Jul 02, 2025

Jul 02, 2025

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - WV News

Jul 02, 2025

Jul 02, 2025

Nektar Raises $115M in Oversubscribed Offering: Major Boost for Immunotherapy Drug Development - Stock Titan

Jul 02, 2025

Jul 01, 2025

Nektar Therapeutics Prices $100 Million Common Stock Offering - MarketScreener

Jul 01, 2025

Jul 01, 2025

Nektar Therapeutics launches proposed public offering - MSN

Jul 01, 2025

Jul 01, 2025

Nektar Therapeutics Announces Pricing of $100 Million Public Off - GuruFocus

Jul 01, 2025

Jul 01, 2025

Nektar Therapeutics (NKTR) Launches Public Offering - GuruFocus

Jul 01, 2025

Jul 01, 2025

Nektar Therapeutics (NKTR) Stock Dips Amid $100M Offering - GuruFocus

Jul 01, 2025

Jun 30, 2025

Nektar Therapeutics dips after announcing equity offering - TradingView

Jun 30, 2025

Jun 30, 2025

Nektar Therapeutics stock falls after announcing public offering By Investing.com - Investing.com Nigeria

Jun 30, 2025

Jun 30, 2025

Nektar Therapeutics Announces Proposed Public Offering | NKTR Stock News - GuruFocus

Jun 30, 2025

Jun 30, 2025

Nektar Therapeutics Announces Proposed Public Offering - WV News

Jun 30, 2025

Jun 30, 2025

Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains - TradingView

Jun 30, 2025

Jun 30, 2025

Immunotherapy Developer Nektar Therapeutics Announces Major Stock Offering to Fuel Clinical Pipeline - Stock Titan

Jun 30, 2025

Jun 28, 2025

Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher? - The Globe and Mail

Jun 28, 2025

Jun 27, 2025

REZOLVE-AD and Rezpegaldesleukin for Atopic Dermatitis, with Jonathan Silverberg, MD, PhD, MPH - HCPLive

Jun 27, 2025

Jun 26, 2025

Vital Signs: Nektar's Dupixent challenger comes better late than never - FirstWord Pharma

Jun 26, 2025

Jun 25, 2025

Nektar Nails Phase 2b Eczema Trial: BTIG Calls It A ‘Pound the Table BUY’, Wainwright Sees $120 Upside - MSN

Jun 25, 2025

Jun 25, 2025

Why Nektar Therapeutics Stock Was Red-Hot Today - MSN

Jun 25, 2025

Jun 25, 2025

Nektar Therapeutics Leads Stock Market Frenzy With Impressive Gains - Finimize

Jun 25, 2025